Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention

被引：0
|
作者：
Itziar Oyagüez
Carmen Suárez
José Luis López-Sendón
José Ramón González-Juanatey
Fernando de Andrés-Nogales
Jorge Suárez
Carlos Polanco
Javier Soto
机构：
[1] Pharmacoeconomics and Outcomes Research Iberia (PORIB),Internal Medicine Department
[2] Hospital La Princesa,Cardiology Department
[3] Hospital Universitario La Paz,Cardiology Department
[4] IdiPaz,undefined
[5] CIBER-CV,undefined
[6] Complejo Hospitalario Universitario de Compostela,undefined
[7] Bristol-Myers Squibb,undefined
[8] Pfizer,undefined
来源：
PharmacoEconomics - Open | 2020年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：485 / 497
页数：12
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
    Oyaguez, Itziar
    Suarez, Carmen
    Luis Lopez-Sendon, Jose
    Ramon Gonzalez-Juanatey, Jose
    de Andres-Nogales, Fernando
    Suarez, Jorge
    Polanco, Carlos
    Soto, Javier
    PHARMACOECONOMICS-OPEN, 2020, 4 (03) : 485 - 497
  • [2] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS
    de Andres-Nogales, F.
    Gay-Pobes, P. R.
    Ines, M.
    Polanco Sanchez, C.
    Alves, D.
    Oyaguez, I
    VALUE IN HEALTH, 2019, 22 : S549 - S550
  • [3] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [4] Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation
    Lip, Gregory Y. H.
    Lanitis, Tereza
    Kongnakorn, Thitima
    Phatak, Hemant
    Chalkiadaki, Corina
    Liu, Xianchen
    Kuznik, Andreas
    Lawrence, Jack
    Dorian, Paul
    CLINICAL THERAPEUTICS, 2015, 37 (11) : 2476 - 2488
  • [5] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [6] Cost-effectiveness of apixaban compared to edoxaban for stroke prevention in non-valvular atrial fibrillation
    Lip, G. Y. H.
    Kongnakorn, T.
    Lanitis, T.
    Phatak, H.
    Liu, J. X. C.
    Kuznik, A.
    Lawrence, J.
    Dorian, P.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1108 - 1109
  • [7] Cost-effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients
    Pradelli, Lorenzo
    Calandriello, Mario
    Di Virgilio, Roberto
    Bellone, Marco
    Tubaro, Marco
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2014, 15 (04) : 101 - 112
  • [8] COST-EFFECTIVENESS OF APIXABAN VERSUS STANDARD OF CARE FOR THE PREVENTION OF STROKE: AN ANALYSIS OF PATIENTS WITH ATRIAL FIBRILLATION IN GRECE
    Athanasakis, K.
    Arzoumanidou, D.
    Karampli, E.
    Armelidou, E.
    Giovas, P.
    Petrikkou, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A524 - A525
  • [9] Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation
    Lanitis, Tereza
    Kongnakorn, Thitima
    Jacobson, Lena
    De Geer, Anna
    THROMBOSIS RESEARCH, 2014, 134 (02) : 278 - 287
  • [10] Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
    Miller, Jeffrey D.
    Ye, Xin
    Lenhart, Gregory M.
    Farr, Amanda M.
    Tran, Oth V.
    Kwong, W. Jackie
    Magnuson, Elizabeth A.
    Weintraub, William S.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2016, 8 : 215 - 226
12345